Sucampo Pharmaceuticals (SCMP) Appoints James J. Egan as COO
More News related to SCMP
- Sucampo Pharma (SCMP) Presents Additional Clinical Data for Lubiprostone
- Sucampo Announces Lubiprostone Data Presented at GASTRO 2009 UEGF/WCOG
- Sucampo Pharma (SCMP) Subsidiary Granted Marketing Authorization for Amitiza in Switzerland
- Sucampo Receives Marketing Authorization for Amitiza(R) in Switzerland for Treatment of Chronic Idiopathic Constipation
- Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Credit Suisse Conference
More News related to Management Changes
- Holly Energy (HEP) Acquires Roadrunner Pipeline from Holly Corp. (HOC); HEP Mentions Enterprise Products (EPD) Transaction
- Dyax (DYAX) Receives FDA Approval of KALBITOR(R) for Treatment of Acute Attacks of Hereditary Angioedema
- UMB Bank (UMBF) Acquires American National Bank Corporate Trust Business
- Center Financial (CLFC) Raises $12.8M In Private Placement
- Markel (MKL) Acquires Majority Interest in Ellicott Dredge Enterprises
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) announced the appointment of James J. Egan as Chief Operating Officer, Sucampo Pharmaceuticals, Inc., a newly-created position, effective September 15, 2009, reporting to Ryuji Ueno, M.D., Ph.D., Ph.D., Chair, and Chief Executive Officer of Sucampo Pharmaceuticals, Inc.
Sucampo also announced that Stanley G. Miele was promoted to President of Sucampo Pharma Americas, Inc., (SPA) and David Dodds was promoted to President of Sucampo Pharma Europe, Ltd. (SPE), effective immediately. Messrs. Dodds and Miele succeed Dr. Ueno in those positions and will report to Mr. Egan. Dr. Ueno will remain the President and CEO of Sucampo Pharma, Ltd. (SPL), SPI's other wholly-owned operating company for Asia and Oceania. In addition, Dr. Ueno will continue to be CEO, Chief Scientific Officer and Chair of Sucampo Pharmaceuticals, Inc. [SM]
Related Categories
Management ChangesStocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
